Bladder Cancer Immunotherapy Building on a history of immune response to bladder cancer Bladder cancer is the sixth most common cancer in the United States and ninth most common worldwide. While the FDA approved the Bacillus Calmette-Guérin (BCG) cancer vaccine in 1990 for the treatment of superficial, non-invasive bladder cancer, oncologists today are excited about a new class of immunotherapies called immune checkpoint inhibitors. New immunotherapies have significantly reduced the risk of recurrence for bladder cancer while also increasing the percentage of patients who see a complete response post-surgery. Dr. Matthew Galsky, of The Tisch Cancer Institute, discusses the potential to further improve outcomes for patients with this disease and answers questions from the audience. In this talk we covered how oncologists predict patient response to immunotherapies, common mutations in bladder cancer, length of treatment, and other topics. Don’t forget to submit your questions to Dr. Galsky. Gynecologic Cancer Immunotherapy Liver Cancer Immunotherapy Skin Cancer and Melanoma Immunotherapy Understanding and Overcoming Barriers to Accessing Cancer Care Blood Cancer Immunotherapy Breast Cancer Immunotherapy Colorectal Cancer Immunotherapy Kidney Cancer Immunotherapy Lung Cancer Immunotherapy Pancreatic Cancer Immunotherapy Prostate Cancer Immunotherapy Intro to CRI Cancer Immunotherapy Basics: Harnessing Our Immune System to Fight Cancer Clinical Trials and Cancer Immunotherapy: Accessing Promising Treatments Patient Perspectives: Immunotherapy and Clinical Trial Experiences Go back to event page Go back Hosts Tamron Hall Award-Winning TV Host, Journalist, Executive Producer, and Philanthropist CRI Experts Julie Brahmer, MD Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Andrea Cercek, MD Memorial Sloan Kettering Cancer Center Luis Diaz Jr., MD Memorial Sloan Kettering Cancer Center Peter E. Fecci, MD, PhD Duke Cancer Center, DukeHealth, and Duke University Lawrence Fong, MD UCSF Helen Diller Family Comprehensive Cancer Center Matthew D. Galsky, MD The Tisch Cancer Institute Sangeeta Goswami, MD, PhD The University of Texas MD Anderson Cancer Center Elizabeth Ann Mittendorf, MD, PhD Dana-Farber/Harvard Cancer Center Kunle Odunsi, MD, PhD University of Chicago Medicine Comprehensive Cancer Center Joseph E. Ravenell, MD Perlmutter Cancer Center NYU Langone Health Marcel van den Brink, MD, PhD Memorial Sloan Kettering Cancer Center Ana I. Velázquez Mañana, MD MSc UCSF Helen Diller Family Comprehensive Cancer Center Robert H. Vonderheide, MD, DPhil University of Pennsylvania Health System Jennifer Wargo, MD, MMSc The University of Texas MD Anderson Cancer Center Jeffrey S. Weber, MD, PhD Perlmutter Cancer Center NYU Langone Health Theodore H. Welling, MD Perlmutter Cancer Center NYU Langone Health CRI ImmunoAdvocates LaToya Bolds-Johnson, PA-C, CAQ-EM Breast Cancer Advocate & Thriver Stephen Estrada Long-term Survivor of Stage 4 Colorectal Cancer Stephanie Gangi Breast Cancer Navigator Sunshine Pegues Lung Cancer Veteran John White Prostate Cancer Veteran CRI Moderators Brian Brewer Cancer Research Institute Sponsors Gold Silver Contributor Friend Host Institutions Request a clinical trials orientation appointment Request Questions? Contact[email protected]
